BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar G, Nandakumar K, Mutalik S, Rao CM. Biologicals to direct nanotherapeutics towards HER2-positive breast cancers. Nanomedicine 2020;27:102197. [PMID: 32275958 DOI: 10.1016/j.nano.2020.102197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Gámez-Chiachio M, Sarrió D, Moreno-Bueno G. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers (Basel) 2022;14:4543. [PMID: 36139701 DOI: 10.3390/cancers14184543] [Reference Citation Analysis]
2 Omidi Y, Mobasher M, Castejon A, Mahmoudi M. Recent advances in nanoscale targeted therapy of HER2-positive breast cancer. J Drug Target 2022;:1-48. [PMID: 35321601 DOI: 10.1080/1061186X.2022.2055045] [Reference Citation Analysis]
3 Dubey SK, Bhatt T, Agrawal M, Saha RN, Saraf S, Saraf S, Alexander A. Application of chitosan modified nanocarriers in breast cancer. Int J Biol Macromol 2022;194:521-38. [PMID: 34822820 DOI: 10.1016/j.ijbiomac.2021.11.095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
4 Shipunova VO, Kolesnikova OA, Kotelnikova PA, Soloviev VD, Popov AA, Proshkina GM, Nikitin MP, Deyev SM. Comparative Evaluation of Engineered Polypeptide Scaffolds in HER2-Targeting Magnetic Nanocarrier Delivery. ACS Omega 2021;6:16000-8. [PMID: 34179645 DOI: 10.1021/acsomega.1c01811] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
5 Zielińska A, Szalata M, Gorczyński A, Karczewski J, Eder P, Severino P, Cabeda JM, Souto EB, Słomski R. Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications. Cancers (Basel) 2021;13:1896. [PMID: 33920840 DOI: 10.3390/cancers13081896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
6 Ghosh G, Panicker L. Protein-nanoparticle interactions and a new insight. Soft Matter 2021;17:3855-75. [PMID: 33885450 DOI: 10.1039/d0sm02050h] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Sankhe R, Pai SRK, Kishore A. Tumour suppression through modulation of neprilysin signaling: A comprehensive review. Eur J Pharmacol 2021;891:173727. [PMID: 33160935 DOI: 10.1016/j.ejphar.2020.173727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yang X, Wu D, Yuan S. Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer. Technol Cancer Res Treat 2020;19:1533033820962140. [PMID: 33034269 DOI: 10.1177/1533033820962140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]